Timber Pharmaceuticals Net Income 2011-2021 | TMBR

Timber Pharmaceuticals net income from 2011 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Timber Pharmaceuticals Annual Net Income
(Millions of US $)
2020 $-15
2020 $-10
2019 $
2019 $-17
2018 $-17
2017 $-19
2016 $-16
2015 $
2014 $-8
2013 $-2
2012 $-0
2012 $-0
2011 $-0
2010 $-0
2010 $
2009 $
Timber Pharmaceuticals Quarterly Net Income
(Millions of US $)
2021-06-30 $-3
2021-03-31 $-2
2020-12-31 $1
2020-09-30 $3
2020-06-30 $-15
2020-04-30 $-2
2020-03-31 $-4
2020-01-31
2019-12-31
2019-10-31 $-2
2019-09-30 $-1
2019-07-31 $-3
2019-06-30 $-0
2019-04-30 $-4
2019-01-31
2018-10-31 $-4
2018-07-31 $-4
2018-04-30 $-4
2018-01-31
2017-10-31 $-4
2017-07-31 $-4
2017-04-30 $-5
2017-01-31
2016-10-31 $-4
2016-07-31 $-5
2016-04-30 $-4
2016-01-31
2015-10-31 $-4
2015-07-31 $-4
2015-04-30 $-4
2015-01-31
2014-12-31 $-2
2014-10-31 $-2
2014-09-30 $-2
2014-07-31 $-2
2014-06-30 $-2
2014-04-30 $-1
2014-03-31 $-1
2013-12-31 $-1
2013-09-30 $-0
2013-06-30 $-0
2013-03-31 $-0
2012-12-31 $-0
2012-09-30
2012-06-30 $-0
2012-03-31 $-0
2011-12-31 $-0
2011-09-30
2011-06-30 $-0
2011-03-31 $-0
2010-12-31 $-0
2010-09-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.027B $0.000B
Timber Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on the development and commercialization of treatments for orphan dermatologic diseases. The Company is initially engaged on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis, tuberous sclerosis complex and localized scleroderma. Timber Pharmaceuticals Inc., formerly known as BioPharmX Corporation, is based in NJ, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.038B 8.59
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.127B 20.54
Biohaven Pharmaceutical Holding (BHVN) United States $8.605B 0.00
Emergent Biosolutions (EBS) United States $2.673B 6.45
Arcus Biosciences (RCUS) United States $2.441B 0.00
Myovant Sciences (MYOV) United Kingdom $1.860B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.754B 0.00
Zymeworks (ZYME) Canada $1.075B 0.00
Ambrx Biopharma (AMAM) United States $0.524B 0.00
SQZ Biotechnologies (SQZ) United States $0.335B 0.00
Enzo Biochem (ENZ) United States $0.158B 15.48